VYNE logo

VYNE Therapeutics (VYNE) Company Overview

Profile

Full Name:

VYNE Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 25, 2018

Indexes:

Not included

Description:

VYNE Therapeutics is a biopharmaceutical company focused on developing innovative treatments for skin and autoimmune diseases. They aim to create effective therapies that improve patients' lives by using advanced science and technology to address unmet medical needs.

Key Details

Price

$2.41

Annual Revenue

$424.00 K(-11.11% YoY)

Annual EPS

-$2.78(+61.81% YoY)

Annual ROE

-47.44%

Beta

1.27

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 13, 2023

Analyst ratings

Recent major analysts updates

Jan 14, 25 HC Wainwright & Co.
Buy
Jan 6, 25 HC Wainwright & Co.
Buy
Dec 23, 24 HC Wainwright & Co.
Buy
Nov 18, 24 BTIG
Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Sep 12, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
Jun 14, 24 HC Wainwright & Co.
Buy
Jun 5, 24 HC Wainwright & Co.
Buy
May 9, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
VYNE
globenewswire.comJanuary 6, 2025

BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025.

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE
globenewswire.comDecember 23, 2024

BRIDGEWATER, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive results from the multiple ascending dose (“MAD”) portion of its Phase 1a SAD/MAD trial of VYN202. The Phase 1a trial was a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of single ascending dose (“SAD”) and MAD components to evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202.

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE
globenewswire.comSeptember 12, 2024

BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose (“SAD”) portion of its ongoing Phase 1a trial of VYN202. The Phase 1a trial is a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of SAD and multiple ascending dose (“MAD”) components to evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202. Findings from the SAD portion of the Phase 1a trial to date are as follows:

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
VYNE
zacks.comAugust 14, 2024

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago.

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
VYNE
globenewswire.comAugust 14, 2024

BRIDGEWATER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and six months ended June 30, 2024 and provided a business update.

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
VYNE
globenewswire.comJune 26, 2024

Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYNE
globenewswire.comJune 13, 2024

VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in 2H'24 BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first healthy volunteers have been dosed in the Phase 1a trial of VYN202.

Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
VYNE
Zacks Investment ResearchMarch 13, 2024

After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
VYNE
Zacks Investment ResearchMarch 8, 2024

VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VYNE Gains on Preclinical Data for IPF Candidate
VYNE Gains on Preclinical Data for IPF Candidate
VYNE Gains on Preclinical Data for IPF Candidate
VYNE
Zacks Investment ResearchApril 20, 2023

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

FAQ

  • What is the ticker symbol for VYNE Therapeutics?
  • Does VYNE Therapeutics pay dividends?
  • What sector is VYNE Therapeutics in?
  • What industry is VYNE Therapeutics in?
  • What country is VYNE Therapeutics based in?
  • When did VYNE Therapeutics go public?
  • Is VYNE Therapeutics in the S&P 500?
  • Is VYNE Therapeutics in the NASDAQ 100?
  • Is VYNE Therapeutics in the Dow Jones?
  • When was VYNE Therapeutics's last earnings report?
  • When does VYNE Therapeutics report earnings?
  • Should I buy VYNE Therapeutics stock now?

What is the ticker symbol for VYNE Therapeutics?

The ticker symbol for VYNE Therapeutics is NASDAQ:VYNE

Does VYNE Therapeutics pay dividends?

No, VYNE Therapeutics does not pay dividends

What sector is VYNE Therapeutics in?

VYNE Therapeutics is in the Healthcare sector

What industry is VYNE Therapeutics in?

VYNE Therapeutics is in the Biotechnology industry

What country is VYNE Therapeutics based in?

VYNE Therapeutics is headquartered in United States

When did VYNE Therapeutics go public?

VYNE Therapeutics's initial public offering (IPO) was on January 25, 2018

Is VYNE Therapeutics in the S&P 500?

No, VYNE Therapeutics is not included in the S&P 500 index

Is VYNE Therapeutics in the NASDAQ 100?

No, VYNE Therapeutics is not included in the NASDAQ 100 index

Is VYNE Therapeutics in the Dow Jones?

No, VYNE Therapeutics is not included in the Dow Jones index

When was VYNE Therapeutics's last earnings report?

VYNE Therapeutics's most recent earnings report was on Nov 7, 2024

When does VYNE Therapeutics report earnings?

The next expected earnings date for VYNE Therapeutics is Feb 28, 2025

Should I buy VYNE Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions